Cui Xuehao, Liang Tingyi, Ji Xunda, Shao Yan, Zhao Peiquan, Li Xiaorong
Department of Ophthalmology, Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin International Joint Research and Development Centre of Ophthalmology and Vision ScienceEye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjing, China.
Department of Ophthalmology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ocul Immunol Inflamm. 2023 Apr;31(3):506-514. doi: 10.1080/09273948.2022.2037659. Epub 2022 Apr 11.
LINC00488 confers oncogenic activity in the progression of some tumors. Hence, the target of the study was about to specify LINC00488-mediated network in retinoblastoma (RB).
LINC00488 expression was tested in RB clinical tissues. siRNA targeting LINC00488 or miR-30a-5p mimic was introduced into RB cell line (Y79) to observe cellular biological functions. The relationship between LINC00488, miR-30a-5p and EPHB2 was verified. Afterward, the role of miR-30a-5p involved in RB through targeted regulation of EPHB2 was probed in vitro and in vivo.
LINC00488 was induced in RB tissue and cells. LINC00488 knockdown or miR-30a-5p upregulation depressed the malignant activities of Y79 cells. LINC00488 could sponge miR-30a-5p that targeted EPHB2. EPHB2, and EPHB2 overexpression counteracted miR-30a-5p restoration-induced inhibition of Y79 cell development in vitro and in vivo.
LINC00488 induces tumorigenicity in RB by binding to miR-30a-5p to target EPHB2, which may offer a new clue of RB treatment from an lncRNA-miRNA-mRNA network.
LINC00488在某些肿瘤进展中具有致癌活性。因此，本研究的目标是明确视网膜母细胞瘤（RB）中LINC00488介导的网络。
检测RB临床组织中LINC00488的表达。将靶向LINC00488的小干扰RNA（siRNA）或miR-30a-5p模拟物导入RB细胞系（Y79），以观察细胞生物学功能。验证LINC00488、miR-30a-5p和EPHB2之间的关系。随后，在体外和体内探讨miR-30a-5p通过靶向调控EPHB2参与RB的作用。
LINC00488在RB组织和细胞中被诱导表达。敲低LINC00488或上调miR-30a-5p可抑制Y79细胞的恶性活性。LINC00488可吸附靶向EPHB2的miR-30a-5p。EPHB2过表达可抵消miR-30a-5p恢复诱导的Y79细胞在体外和体内发育的抑制作用。
LINC00488通过与miR-30a-5p结合靶向EPHB2诱导RB的致瘤性，这可能从lncRNA-miRNA-mRNA网络为RB治疗提供新线索。
